| Literature DB >> 33800363 |
Linhua Tian1, Elzafir B Elsheikh1, Paul N Patrone2, Anthony J Kearsley2, Adolfas K Gaigalas1, Sarah Inwood1, Sheng Lin-Gibson1, Dominic Esposito3, Lili Wang1.
Abstract
Quantitative and robust serology assays are critical measurements underpinning global COVID-19 response to diagnostic, surveillance, and vaccine development. Here, we report a proof-of-concept approach for the development of quantitative, multiplexed flow cytometry-based serological and neutralization assays. The serology assays test the IgG and IgM against both the full-length spike antigens and the receptor binding domain (RBD) of the spike antigen. Benchmarking against an RBD-specific SARS-CoV IgG reference standard, the anti-SARS-CoV-2 RBD antibody titer was quantified in the range of 37.6 µg/mL to 31.0 ng/mL. The quantitative assays are highly specific with no correlative cross-reactivity with the spike proteins of MERS, SARS1, OC43 and HKU1 viruses. We further demonstrated good correlation between anti-RBD antibody titers and neutralizing antibody titers. The suite of serology and neutralization assays help to improve measurement confidence and are complementary and foundational for clinical and epidemiologic studies.Entities:
Keywords: IgG; IgM; RBD; SARS-CoV-2 virus; cross reactivity; monoclonal antibody reference standard; neutralization assay; quantitative serology assays; sensitivity and specificity; spike
Mesh：
Substances：
Year: 2021 PMID： 33800363 PMCID： PMC7962843 DOI： 10.3390/ijms22052723
Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923